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ABSTRACT 
Background: There is controversy about which outcome parameters should be employed to 
assess substance use treatment. Subjective measures of medication-assisted treatment (MAT) 
of opioid dependence are increasingly important. However, while patients’ perspectives have 
been examined, the caregivers’ views remain largely unknown. Here, we explore how 
physicians evaluate MAT, and which predictors are most relevant. Methods: We conducted a 
retrospective cohort study of all MAT episodes with oral opioid agonists in the canton of 
Zurich between 1998 and 2013 using a case register. Termination forms of the register 
include a physician-completed assessment on the course of the treatment episode. Mixed 
model analysis was applied to determine relevant predictors. Results: The analysis was based 
on 17,234 episodes from 7,432 patients. Mean global assessment of the course of MAT was 
'moderate'. The most important predictors for treatment evaluation by physicians were 
treatment break off as reason for termination (p<0.0001), psychological improvement 
throughout treatment (p<0.0001), wish for abstinence from the substitute (p<0.0001), social 
integration index at termination (p<0.0001), and social (p<0.0001) as well as medical 
(p<0.0001) improvement. The negative association of treatment break off with MAT 
assessment was more pronounced in semi-rural than urban areas (p<0.0001). Conclusion: 
Predictors relating to the well-being and functioning of the patient as well as the reasons 
underlying treatment termination appear to be more important for the treating physician’s 
evaluation of medication-assisted treatment episodes than on-going substance use. Coming 
off the opioid medication plays a central role, independent of ongoing illicit substance use. 
 
KEYWORDS: Maintenance therapy; replacement therapy; subjective; heroin; opiate; 
provider; predictor  
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1. INTRODUCTION 
 Opioid dependence is a chronic disorder characterized by relapse and rare long-term 
cessation (Genberg et al., 2011; Termorshuizen, 2005). It often entails negative sequelae for 
the affected individuals and their families, and substantial public health consequences for 
society as a whole (Whiteford et al., 2013). In 2014, the prevalence of opioid dependence was 
estimated at 0.4% for the European Union (European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), 2014). Medication-assisted treatment (MAT) with methadone, l-
polamidone, buprenorphine or slow-release oral morphine sulphate is considered to be the 
treatment of first choice (Dole and Nyswander, 1965; Mattick et al., 2014, 2009; Ward et al., 
1999; WHO, 2009). Due to the chronicity of opioid dependence, current treatment guidelines 
favor the open-end nature of MAT, sometimes required to continue lifelong (APA, 2006; 
Swiss Society of Addiction Medicine (SSAM), 2013). In some countries, legal regulations 
still call for complete abstinence (including opioid substitutes) as mandatory treatment goal, 
but abstinence-oriented therapy is often unsuccessful due to high relapse rates with the risk of 
deteriorating psychosocial conditions or even death due to overdose after lost tolerance to 
opioids (Caplehorn et al., 1994; Merrall et al., 2010; Strang, 2003). The rate of spontaneous or 
professionally assisted remission remains controversial. A recent review found a rate of 9% 
annually (Calabria et al., 2010). Typically, however, when access to MAT is low-threshold, 
many opioid-dependent patients enter and leave treatment repeatedly in the course of their 
disorder (Bell et al., 2006), which, among other reasons (such as changing the responsible 
physician), may reflect patients’ desire for more independence and ‘getting clean’, i.e., 
complete abstinence including the substitute (Gutwinski et al., 2014; Winstock et al., 2011). 
There has been intensive debate on suitable outcome parameters in the evaluation of 
substance use treatment in general, and MAT in particular (Bühringer, 2012; Donovan et al., 
2012; Tiffany et al., 2012; Uchtenhagen, 2012). MAT is associated with a reduction in 
substance use, mortality, treatment dropouts, HIV infections, psychosocial symptom load and 
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delinquency, and an overall increase in quality of life (Brugal et al., 2005; Cacciola, 2001; 
Deck et al., 2009; Feelemyer et al., 2014; MacArthur et al., 2012; Mattick et al., 2009). Most 
treatment studies focused on putative objective parameters, while the subjective outcomes of 
MAT have received less attention. However, there is an increasing recognition that these 
constitute essential measures of MAT quality (Tiffany et al., 2012; Trujols et al., 2011; 
Uchtenhagen, 2015). Few studies have investigated subjective views of MAT episodes 
(Montagne, 2002; Stancliff, 2002), and, if so, mostly addressed patient satisfaction (Kelly et 
al., 2010; Marchand et al., 2011; Trujols et al., 2012). Fewer studies still have investigated the 
views of treatment providers (Becker and Fiellin, 2006). These mostly concentrated on meta-
aspects, such as the provision of MAT and harm reduction (Deren et al., 2011; Forman et al., 
2001; Notley et al., 2014), barriers to care (Schulte et al., 2013), the diversion and misuse of 
the substitute (Larance et al., 2011), reasons for dropout and treatment retention (Gutwinski et 
al., 2014) or combinations of the above (Besson et al., 2014). To our knowledge, Trujols et al. 
(2011) conducted the only study investigating both provider and patient views of single MAT 
episodes (Trujols et al., 2011). Using patient and clinician versions of the Global Impression 
of Improvement Scale in a sample of 110 MAT patients, they demonstrated that patients and 
providers often have discordant perceptions of improvement in treatment (Trujols et al., 
2011). It remains unclear, however, which predictors determine physicians’ assessments of 
MAT course and whether these are similar to the outcomes used in MAT evaluation. They 
reflect on providers‘ implicit treatment goals and conceptualisation of MAT, which may 
differ from those of patients, public health policy makers or researchers investigating MAT. 
Relevant predictors may be based on personal biases as well as scientific evidence and legal 
regulations. They may influence attitude towards the patient, and physician as well as patient 
behavior, such as the decision to enter, stay in or leave treatment, or shared-decision making 
during treatment. 
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 The aim of this study was to determine the predictors of physicians’ assessment of 
MAT using data from Zurich, Switzerland. 
2. METHODS 
 Zurich is both the most populous Swiss canton and the largest Swiss city. Following 
the development of open drug scenes, harm reduction measures were scaled up massively in 
the 1990s. MAT has since been offered on a low-threshold basis with opioid dependence as 
single entry criterion and wide accessibility. It is reimbursed by mandatory health insurance, 
and patients can freely choose their provider. Since 1991, the canton monitors MAT with 
methadone, buprenorphine, and recently slow-release oral morphine sulphate, with an 
anonymized treatment case register (Nordt and Stohler, 2006). Heroin-assisted treatment is 
excluded and evaluated separately. Physicians are required to complete a questionnaire at 
initiation and termination of treatment, as well as twice yearly or when changing the 
substitute. Collection and evaluation of data are in accordance with the data protection law of 
the canton of Zürich and the local ethics committee approved the analysis. 
 For analysis of clinicians’ evaluation of treatment episodes, we used the question on 
“global assessment of treatment course“, which physicians answered on a five-point Likert 
scale (1 “very unfavorable“, 2 “rather unfavorable“, 3 “moderate“, 4 “rather favorable“, 5 
“very favorable“) at termination of treatment. 
 The question on reasons for treatment termination in the evaluation questionnaire 
could originally be answered in seven ways: 1 “regular, abstinent (from substitute)”, 2 
“regular, in mutual consent“, 3 “formal break off by patient”, 4 “formal break off by 
physician”, 5 “loss of contact”, 6 “patient deceased” and 7 “other (to be specified)”. For the 
multivariate analysis, we grouped those answers as follows: abstinent (option 1), regular 
(including option 2, 6 and 7), and treatment break off (option 3, 4 and 5). Physicians were 
also asked to report changes in psychological, medical and social conditions of the patient 
throughout treatment and could answer on a three-point scale 1 “worsened”, 2 “unaltered”, 3 
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“improved”. Moreover, we used data from the entry questionnaire on these conditions, coded 
1 “(rather) bad”, 2 “moderate”, 3 “(rather) good”. Using the mean of at least four of six items 
(having a full or part time job, earning one’s living; living in a flat; having a partnership; good 
family relations; having friends outside the drug scene) we calculated a social integration 
index, ranging between 0 and 1 (Cronbach’s Alpha = 0.58). 
 Furthermore, the questionnaire comprised items on the use of heroin, cocaine, illicit 
benzodiazepines and alcohol in the past 30 days before treatment termination, each answered 
on a four-point scale coded 1 “none”, 2 “occasionally”, 3 “(almost) daily”, 4 “several times a 
day”. We also used data on age of onset of heroin use (dichotomized as 18 years or earlier 
versus 19 years or later), duration of opioid use (in decades) and lifetime intravenous use. 
Moreover, we included age (in decades and centered at 30 years), number of MAT episodes 
and duration of current episode (in months, logarithmized) as predictors. Finally, treatment 
providers were characterized by type (private practice versus specialized institution) and by 
area. The latter was operationalized as “urban”, corresponding to the city of Zurich, or “semi-
rural”, corresponding to the surrounding canton. 
 Between 1991 and the end of October, 2014, 34,082 treatment episodes of 11,749 
patients were collected. A careful check for overlapping treatment episodes led to the 
exclusion of 201 episodes. Although we used information of all entry forms for each patient, 
gender (6%), ever injecting status (8%), and nationality (13%) remained unknown for some 
patients. For about 28% of patients we could not obtain a plausible year of first regular heroin 
use (not before their 12th year of age, not after their first MAT according to our case register, 
difference in cases of multiple entry forms three years or less; Nordt and Stohler, 2006). As 
there were also missing data in time-dependent predictors that are most likely correlated 
within individuals (e.g., frequency of drug use, social integration), we applied the multiple 
imputation procedure of SPSS 22 in addition to a complete case analysis that could only use 
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about 26% of the available data. We did not impute reasons of cessation, as some may occur 
repeatedly in a patient except in the case of death. 
 As our case register is far from being a balanced repeated-measure dataset – where all 
patients provide the same number of follow-up datasets within the similar time period – we 
applied a two-stage approach. The first stage included invariant personal characteristics where 
we used the mean value of all predictors of our model of interest (MOI), with fully 
conditional specification including one-way interactions for nominal predictors (i.e., gender 
nationality, and injecting status). The number of imputed datasets was set to ten. The third 
predictor requiring imputation on the first stage was year of first regular heroin use which was 
also checked for plausibility as described above, and in order to keep consistency, we made 
small correction where appropriate (< 2% of all imputed values). The second-stage imputation 
used for all time-dependent MOI variables additional ‘difference variables’ (indicating the 
difference of an observed value to the person’s specific mean value of the first stages) for 
each first-stage imputed dataset separately. Finally, the imputed values of treatment 
evaluation, change in psychological, medical and social condition, of frequency of drug use, 
social integration, initial psychological, medical and social condition were calculated by the 
imputed mean and difference value that was converted into outcome categories. Similarly, if 
the imputed values of the social integration index were outside the range of 0-1, they were set 
to the respective limit value. 
 We used mixed models analysis in SAS 9.4 for the MOI of treatment evaluation with 
patient ID as repeated subject identification. The analysis was only applied on treatment 
episodes that ended between January 1st , 1998 and December 31st, 2013, as frequency of drug 
use was not part of cessation forms before 1998. The selection criteria described above 
resulted in a total of 20,146 datasets from 8,002 patients. A valid value of treatment 
evaluation was present in 14,574 episodes, but a reason given for treatment cessation was 
obtained from 17,247 episodes. We report the mixed model analysis results for the imputed 
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dataset but also provide the results of the complete dataset (see supplementary table1) as 
multiple imputation has both potential and pitfalls (Sterne et al., 2009). Interactions were 
tested with reasons of MAT termination, and provider location and type, but only significant 
results are reported. 
3. RESULTS 
 Unless otherwise indicated, all results reported refer to the imputed dataset. The 
annual number of discontinued MAT episodes declined rather linearly from 1,773 in 1998 to 
847 in 2013, with slight transient increases in 2003, 2004 and 2008 (Figure 1). Seventy-one 
per cent of patients in our dataset were male. Patient nationality was Swiss in 79%, a number 
comparable to other Swiss studies (Baumeister et al., 2014). While data on ethnicity is not 
collected in the register, most non-Swiss patients are from European countries and therefore 
also of Caucasian ethnicity. Mean age at termination was 32 years. The median duration of 
treatment episodes was 199 days. The duration was longest for the fourth episode with 249 
days and slightly decreased for further episodes. The mean number of episodes per patient 
was 2.3, with a maximum of 26 episodes. The majority of episodes were conducted in Zurich-
city (60%) as opposed to semi-rural areas of the canton (40%). Physicians in private practice 
were involved in fifty-four per cent of the MAT episodes, whereas 46% worked in 
institutions. There were 4434 and 4840 treatment episodes from 187 and 327 different private 
practices in urban versus semi-rural areas, respectively. Concerning institutions, we registered 
7656 and 3216 treatment episodes from 16 and 15 institutions in urban and semi-rural areas, 
respectively. 
 Figure 2 depicts the mean scores of MAT physicians’ global assessment of treatment 
course by year. It can be seen that they remain very stable over the years, ranging between 
2.92 (2002) and 3.15 (2013), corresponding to a “moderate” value overall.  
                                                 
1 Supplementary material can be found by accessing the online version of this paper at 
http://dx.doi.org and by entering doi:... 
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 Physician-reported reasons for treatment termination over time are depicted in figure 
3. Most prevalent for the whole study period was the reason “regular, in mutual consent” 
(40.5%). Its frequency was highest at 47% in 2005 and declined somewhat afterwards with a 
slight increase in years 2008, 2010 and 2013. The second most prevalent reason was “loss of 
contact” (24.9%), peaking at 33% in 2000 and declining to 18% in 2013. It is followed by 
“abstinence” (12.6%), which was most common in 1999 with 18%, declining to 10% in 2007 
and again increasing to 15% in 2013. Less common reasons were “formal break off by 
patient” (10.1%), and “formal break off by physician” (5.9%). The proportion of death as 
reason for termination (4.3%) has been increasing steadily since 1998. This finding is mostly 
connected to the decreasing annual number of overall treatment cessations during the study 
period (Figure 1). Actually, the number of deaths per person years in treatment remained 
rather constant throughout the study period between 1998 and 2013. “Other” reasons were 
rare (1.6%). 
 The mixed-model analysis overall included 17,234 episodes of 7,432 patients. Due to 
the size of the dataset most p-values are small. Model 1 shows that the physician assessment 
of treatment course was almost 1 point elevated if the reason for MAT termination was 
“abstinent”, irrespective of whether the physician worked in a semi-rural or an urban area. In 
cases with a break off as reason for MAT termination, this lead to a poorer assessment score 
(-0.68) for physicians in semi-rural than for those in urban areas (-0.68+0.25=-0.43). 
Physician assessment of treatment course showed no difference between both areas in cases 
with regular termination. In contrast to area, the type of the institution (private practice versus 
specialized institution) did not interact with reason for MAT termination. Besides the two 
physician variables, model 2 included a broad variety of patient characteristics that showed 
similar estimates as in model 3, in which predictors of model 1 were added. In contrast, the 
estimate for ‘abstinent’ in model 3 is substantially lower with 0.38 than in model 1 with 0.95. 
The strongest association in model 3 was observed for treatment break off as reason for MAT 
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termination (negative), followed by change in psychological condition throughout the MAT 
episode, abstinence as termination reason, the social index score at termination, and change in 
social and, albeit smaller, medical condition (all positive). In model 3, there was still a 
relevant interaction between area and treatment break off, with a less negative effect of 
treatment break off on MAT evaluation in urban compared to semi-rural areas. The detailed 
results of the analysis are displayed in Table 1. 
4. DISCUSSION 
 To our knowledge, this is the first study providing insights into how physicians judge 
the success of MAT episodes in clinical practice. The overall “moderate” evaluation across 
the whole sample calls into mind the chronicity and complexity of the treatment of opioid 
dependence (McLellan et al., 2000). Our findings are of particular interest in light of the 
debate about which outcome parameters to apply in the assessment of substance use treatment 
(Bühringer, 2012; Donovan et al., 2012; Miller and Miller, 2009; Tiffany et al., 2012; 
Uchtenhagen, 2015). Some researchers have argued that substance use is the most suitable 
parameter for treatment success and should thus be the primary outcome of treatment 
evaluation (Donovan et al., 2012). However, in our study the concomitant use of substances 
only had a small effect. The most important predictors that we identified relate to 
psychological and medical patient health, social integration and the circumstances of 
treatment termination. MAT providers seem to apply broad criteria, targeting various facets of 
patients’ well-being, and prescription and dispensing of the substitute are ideally accompanied 
by psychosocial and medical interventions. While the concentration on substance use as 
primary outcome parameter may have its merits in the comparative evaluation of different 
maintenance agonists, it may be insufficient when evaluating MAT as a whole in clinical 
practice, and is not reflected in the predictors influencing clinicians’ evaluation which we 
identified. 
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 The physician’s perception of improvement of the patients' psychological condition 
throughout MAT was of great importance for the evaluation of the MAT course, as were, 
albeit to a lesser extent, social and medical improvement. The relevance of psychological 
improvement as a treatment goal of providers in general addiction treatment has been 
described in a recent study by Joosten et al. (2011). These perceptions likely reflect an 
improvement in health as well as in social reintegration. Furthermore, given the high 
proportion of opioid dependent patients with comorbid psychiatric disorders, the reduction of 
psychopathological symptoms is a legitimate and important goal of treatment. It is 
increasingly recognized that outcomes reflecting these changes, such as psychosocial 
symptom burden or quality of life measures, should be included in studies on the 
effectiveness of substance use treatment (Nosyk et al., 2011). Our findings underline the 
importance of these parameters in clinical practice. 
 We used the information on social integration to calculate an index score from several 
separate predictors. This composite score includes details on work, living conditions and 
social relations at the time of MAT termination. It shows a strong positive relationship with 
treatment evaluation, emphasizing the significance of social reintegration in the evaluation of 
MAT. Social functioning has also been associated with patients’ satisfaction with MAT 
(Trujols et al., 2012), and may therefore constitute an important common outcome parameter 
for patients as well as providers. Of course, as we collected no data on this, we cannot rule out 
that socially well-integrated patients are less likely to suffer from psychiatric comorbidities. 
Such comorbidities may negatively affect treatment course as well as interaction with 
treatment providers. Physicians may also be more likely to judge these patients as ‘difficult’ 
or hard-to-treat, and MAT itself as less successful. 
 In our study, circumstances underlying MAT termination were grouped as “abstinent” 
(i.e., coming off the substitute), “regular” (including mutual consent and patient death) and 
“break off” (premature termination due to patient or provider initiative or loss of contact). The 
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strongest predictor in our final multivariate model was treatment break off, which had a 
negative effect compared to regular termination of MAT. Break off may occur for various 
reasons on the patients' as well as the physicians' side. For instance, it may occur due to the 
desire for more independence, of medication or the sometimes rigid MAT setting. For some 
severely disintegrated comorbid patients, the requirements of regular, daily to weekly 
appointments to collect the substitute may be too demanding. Break off may also result from 
difficulties in the therapist-patient relationship, repeated breaking of rules or even violent 
threats or behaviors. Most likely, premature termination of MAT will occur in a situation 
where not all treatment goals (whatever these are) have been reached, which could further 
explain the negative association. 
 This association was stronger for semi-rural than urban areas. Treatment in semi-rural 
areas may be less anonymous, and long-term personal knowledge between provider and 
patient may be more common in these closer-knit settings, possibly leading to a more severe 
judgment of irregular treatment cessation and more associated concerns. Because there are 
fewer providers in semi-rural areas, the possibilities for a patient to reinitiate MAT with a 
different provider may be limited as compared to urban areas, making treatment break off 
more significant as patients may end up with insufficient care. There are also reports about 
stronger stigmatization of substance users by the general population as well as mental health 
professionals in more rural settings (Oser et al., 2013; Yannessa et al., 2008), which may lead 
to more negative assessments. 
 Generally, the relevance of this predictor is consistent with the use of treatment 
dropout as outcome parameter in trials investigating the effectiveness of MAT. While MAT is 
very effective in retaining patients in treatment, abrupt termination for a variety of reasons 
remains problematic from the providers’ view. These findings may reflect the medical 
conceptualization of MAT as an often open-end long-term treatment of a chronic disorder. 
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Abstinence (i.e., stopping or tapering the substitute opioid, ‘getting clean’) as reason for 
termination of MAT equally showed a strong association (even the strongest in bivariate 
analysis): When patients were coming off the substitute, providers were likely to rate the 
treatment course more positive than with other regular circumstances of treatment cessation. 
 In the past three decades, the view on abstinence has changed from the ultimate goal 
of treatment to one possible option among others in maintaining well-being of the patient 
(Uchtenhagen, 2013). This is also reflected in the current MAT recommendations of the 
Swiss Society for Addiction Medicine, which endorse a long-term, open-ended approach and 
recommend exploring with the patient the advantages and disadvantages of abstinence from 
the substitute (Swiss Society of Addiction Medicine (SSAM), 2013). While we did not find 
evidence for a change of the effect of abstinence on treatment evaluation with time since 
1998, our findings illustrate that it remains an important option in the treatment of opioid 
dependence. One may argue that the positive association does not reflect the value of 
abstinence per se, but rather other factors, such as the mutual consent about treatment goals or 
the stable situation of a patient deciding to come off the substitute in agreement with the 
responsible physician. However, these factors were also applicable for those MAT episodes 
with other regular reasons for termination in mutual agreement. The effect remained 
significant when controlling for substance use in the last 30 days of the MAT episode. Thus, 
even if patients were still using illicit drugs, physicians rated the treatment course more 
favorable when patients opted for tapering of the opioid substitute. Moreover, we statistically 
controlled for a wide variety of other predictors such as duration of treatment and, most 
importantly, improvement of social, medical and psychological conditions as perceived by the 
physician. Future research could investigate the role abstinence plays for MAT-providing 
physicians in more detail with qualitative methods. 
 There has been increasing advocacy for a patient-centered approach in MAT taking 
into account the preferences and resources of the patient during treatment, and subjective 
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well-being and quality of life for outcome research (Miller and Miller, 2009; Uchtenhagen, 
2015). The strong association of physician-perceived course of treatment with abstinence as 
reason for MAT termination may be the very expression of such a patient-centered approach, 
since clinical experience as well as studies show that the desire to come off MAT is still very 
widespread among patients (Gutwinski et al., 2014; Winstock et al., 2011). It may reflect the 
wish to be independent and less restricted by the necessity for regular medication use or the 
occasionally rigid treatment settings. Furthermore, unlike some other health systems, it is 
unproblematic to re-enter treatment in Switzerland when abstinence from the substitute fails, 
lowering the threshold to explore other, drug-free, treatment options in accordance with the 
patient and his individual situation. 
4.1 Strength and limitations 
 Our study has certain limitations. It is based on routine data with missing values and 
we cannot completely rule out that there is a systematic pattern related to treatment 
evaluation. Furthermore, we did not have information on the providing physicians’ specialty 
(psychiatry vs. GP). Due to the nature of our treatment register, all data were provided by the 
respective physicians responsible for MAT. As such, predictors and assessment may be 
influenced by personal biases. Although we are explicitly investigating subjective 
measurements rather than objective outcomes, having some putative objective parameters 
collected by independent third parties would be a valuable supplement for the future. Finally, 
as this study is based on questionnaires completed at termination of MAT, it does not include 
currently on-going MAT episodes. Among these, there may be some with highest continuity 
i.e., running for a long time with the same physician and the same opioid substitute. These 
subjects with high adherence may be rated more favorable. 
 Among the strengths of this study is the incorporation of data from a large number of 
MAT episodes and patients over a long period of time across different providers (institution-
based and private practice; urban and semi-rural). Furthermore, we statistically controlled for 
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a multitude of predictors by using mixed model analysis. Finally, our study considers the 
evaluation of whole MAT episodes, as opposed to outcomes at certain time points after 
initiation, which may be less adequate for chronic disorders. 
4.2 Conclusion 
 Our results provide novel insights into the way treating physicians evaluate the course 
of MAT in their patients. The mean assessment values at the end of treatment episodes were 
moderate. We identified several important predictors, which shed some light on the 
parameters MAT providing physicians apply when judging the success of failure of their 
treatment. Among them are psychological, social and/or medical improvements, social 
integration, and the reasons underlying treatment termination, namely treatment break off or 
coming off the substitute. Some, but not all, of these predictors are in agreement with the 
commonly used outcome parameters of MAT evaluation studies, such as treatment retention, 
substance use or psychosocial well-being. 
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FIGURE LEGENDS 
 
Figure 1 Number of terminated medication-assisted treatment episodes by year. 
 
 
Figure 2 Treatment evaluation at termination of medication-assisted treatment, 1998-2013 (1 
“very unfavorable”, 2 “rather unfavorable”, 3 “moderate”, 4 “rather favorable”, 5 “very 
favorable”). 
 
 
Figure 3 Physician-reported reasons for termination of medication-assisted treatment episode 
from 1998 until 2013. 
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Table 1 Mixed model analysis for physicians’ assessment of treatment course (imputed dataset). 
 Model 1 Model 2 Model 3 
 
Imputed dataset Imputed dataset Imputed dataset 
Reason for MAT1 termination Estimate SE P Estimate SE P Estimate SE P 
 intercept 3.13 0.02 <.0001 0.64 0.06 <.0001 1.01 0.06 <.0001 
 abstinent 0.95 0.03 <.0001 
   
0.38 0.03 <.0001 
 break off -0.68 0.03 <.0001 
   
-0.47 0.02 <.0001 
 Urban3*abstinent -0.08 0.04 0.0701 
   
-0.06 0.04 0.0951 
 urban3*break off 0.25 0.03 <.0001 (City) 0.04 0.02 0.0054 0.20 0.02 <.0001 
 urban3*regular 0.04 0.02 0.0887 
   
0.01 0.02 0.6631 
Institution versus private practice 
   
0.08 0.02 <.0001 0.07 0.02 <.0001 
Change in psychological condition 
   
0.52 0.01 <.0001 0.44 0.01 <.0001 
Change in medical condition 
   
0.17 0.02 <.0001 0.16 0.02 <.0001 
Change in social condition 
   
0.29 0.02 <.0001 0.26 0.02 <.0001 
Social Index Score at termination 
   
0.39 0.03 <.0001 0.35 0.03 <.0001 
Treatment duration (ln of months) 
   
0.04 0.00 <.0001 0.04 0.00 <.0001 
Use of heroin4 
   
-0.11 0.01 <.0001 -0.07 0.01 <.0001 
Use of cocaine4 
   
-0.05 0.01 0.0002 -0.04 0.01 0.0025 
Use of benzodiazepines4 
   
-0.05 0.01 <.0001 -0.05 0.01 <.0001 
Use of alcohol4 
   
-0.03 0.01 0.0082 -0.03 0.01 0.0061 
Psychological condition at treatment entry 
   
0.06 0.01 <.0001 0.06 0.01 <.0001 
Medical condition at treatment entry 
   
0.05 0.01 <.0001 0.05 0.01 <.0001 
Social condition at treatment entry 
   
0.09 0.01 <.0001 0.08 0.01 <.0001 
Number of MAT1 episodes 
   
-0.01 0.00 <.0001 -0.01 0.00 <.0001 
Age (in decades, rescaled 30 years) 
   
0.05 0.02 0.0298 0.04 0.02 0.0895 
Onset with 18 years or younger 
   
0.02 0.03 0.5203 0.01 0.03 0.6572 
Duration of opioid use 
   
0.00 0.03 0.8959 0.00 0.02 0.9919 
Lifetime history of injection use 
   
0.02 0.02 0.3836 0.00 0.02 0.9986 
 
         
N episodes 17234 
  
17234 
  
17234 
  
N patients 7432 
  
7432 
  
7432 
  
Max episodes of patient 26 
  
26 
  
26 
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-2 Log-Likelihood 46940.1 (SD=54.0) 
 
42370.2 (SD=70.1) 
 
41163.4 (SD=89.5) 
 
BIC 46958.0 (SD=54.1) 
 
42388.0 (SD=70.1) 
 
41181.3 (SD=89.5) 
 
 
         
Covariances 
         
Patient 0.27 (SD=0.00) 
 
0.16 (SD=0.00) 
 
0.14 (SD=0.00) 
 
Residual 0.69 (SD=0.00) 
 
0.56 (SD=0.00) 
 
0.52 (SD=0.00) 
 1MAT = medication-assisted treatment; 2with “regular, in mutual consent” as reference category; 3urban versus semi-rural; 4during 30 days before discontinuation of medication-
assisted treatment episode 
 
